Printer Friendly Printed from http://www.researchandmarkets.com/reports/973 Drugs of Tomorrow: Cancer Overview Description: The oncology market will show dramatic development in both overall size and content over the next decade. As the value of the market for traditional therapies is driven down, and more innovative therapies are launched, pharmaceutical companies will need to adapt their product development and marketing strategies. Datamonitor’s Drugs of Tomorrow: Cancer Overview analyses the current state and future trends in the cancer market, with reference to both treatment classes, and dominant companies. Ten tumor types are examined, including evaluation of current treatment regimens and unmet needs. Pipeline products in clinical trials are presented, with detailed analyses of all phase III agents, and sales forecasting until 2010. An extensive analysis of key pharmaceutical companies and biotechnology companies is also presented. Contents: CONTACT DETAILS EXECUTIVE SUMMARY Scope Datamonitor insight into the cancer market The traditional treatment classes of cytotoxics, hormonals and adjuncts should continue to achieve strong sales in the short-term with the launch of novel efficacious agents, which complement the activity of innovative therapeutics The cancer market will see continued strong growth of the immunotherapies class and development of other innovative drug classes. Pharmaceutical companies should invest in the development or in-licensing of innovative cancer treatments to maintain market share Over the next decade, the rising incidence of most tumor types, and the higher cost of novel treatments, should ensure that the value of the cancer market continues to show strong growth year-on-year. This will ensure return on research investment for pharmaceutical developers Beyond 2010, the introduction of next-generation innovative therapies should enable further extension of survival and quality of life, eventually reducing cancer from a life-threatening illness to a well managed chronic illness. Market preference will shift towards those treatments that demonstrate the most favorable toxicity profiles in addition to excellent efficacy Summary analysis Key metrics CANCER MARKET REVIEW Background to the cancer market Cancer market segmentation by drug class Defining the cancer market Cytotoxic therapies Hormonal therapies Innovative therapies Adjunct therapies Market share by class Cancer market segmentation by company Research and development (R&D) investment Company pipelines Adjuncts review Hematopoietic growth factors (HGFs) Anti-emetics Bisphosphonates Analgesics Cytotoxics review Alkylating agents Anti-metabolites Cytotoxic antibiotics Vinka alkaloids and etoposide Other cytotoxics Hormonals review LHRH agonists Anti-estrogens Anti-androgens Progestagens Aromatase inhibitors Innovatives review Immunotherapies Growth inhibitors Gene therapies Antisense Other innovatives DISEASE REVIEW Introduction Breast cancer Disease description Epidemiology Current treatments Unmet needs Prostate cancer Disease description Epidemiology Current treatments Unmet needs Lung cancer Disease description Epidemiology Current treatments Unmet needs Colorectal cancer Disease description Epidemiology Current treatments Unmet needs Leukemia Disease description Epidemiology Current treatments Unmet needs Ovarian cancer Disease description Epidemiology Current treatments Unmet needs Brain cancer Disease description Epidemiology Current treatments Unmet needs Pancreatic cancer Disease description Epidemiology Current treatments Unmet needs Head and neck cancer Disease description Epidemiology Current treatments Unmet needs Malignant melanoma Disease description Epidemiology Current treatments Unmet needs PIPELINE ANALYSIS Introduction Classification of compounds Summary of cancer pipeline Breast cancer Early-stage compounds Late-stage compounds Prostate cancer Early-stage compounds Late-stage compounds Lung cancer Early-stage compounds Late-stage compounds Colorectal cancer Early-stage compounds Late-stage compounds Leukemia Early-stage compounds Late-stage compounds Ovarian cancer Early-stage compounds Late-stage compounds Brain cancer Early-stage compounds Late-stage compounds Pancreatic cancer Early-stage compounds Late-stage compounds Head and neck cancer Early-stage compounds Late-stage compounds Malignant melanoma Early-stage compounds Late-stage compounds COMPANY ANALYSIS Introduction Cancer market leaders Bristol-Myers Squibb Johnson & Johnson AstraZeneca Aventis Novartis Amgen GlaxoSmithKline Pharmacia Roche Schering-Plough Eli Lilly Emerging biotechnology companies Genentech ImClone OSI Pharmaceuticals ISIS Pharmaceuticals Genta Cancer pipeline summary Pipeline analysis by phase Pipeline analysis by indication Pipeline analysis by drug class FUTURE FOCUS Forecasting methodology Predicting first year market share Drug class growth Individual drug growth Influencing factors Influencing factors Increased prevalence Launch of new drug classes Expansion of existing drug classes Increased use of combination therapies Increased diagnosis Patent expiry and genericization Cost containment MediCare reformation Disease management Expansion of the cancer market Forecast incidence Forecast prevalence Market growth Forecast for novel agents in breast cancer treatment Breast cancer market overview Datamonitor opinion: Evista Datamonitor opinion: Gemzar Datamonitor opinion: Alimta Datamonitor opinion: Faslodex Datamonitor opinion: Genasense Datamonitor opinion: Tesmilifene Forecast for novel agents in prostate cancer treatment Prostate cancer market overview Datamonitor opinion: Eligard Datamonitor opinion: Atrasentan Datamonitor opinion: Plenaxis Datamonitor opinion: Provenge Forecast for novel agents in lung cancer treatment Lung cancer market overview Datamonitor opinion: Iressa Datamonitor opinion: ISIS 3521 Datamonitor opinion: BMS-184476 Datamonitor opinion: Navelbine Forecast for novel agents in colorectal cancer treatment Colorectal cancer market overview Datamonitor opinion: Orathecin Datamonitor opinion: Avastin Datamonitor opinion: Avicine Forecast for novel agents in niche cancers treatment Niche cancers market overview Datamonitor opinion: Gemzar Datamonitor opinion: IntraDose Datamonitor opinion: PEG-Intron A Datamonitor opinion: Advexin Datamonitor opinion: Allovectin-7 Datamonitor opinion: Erbitux Datamonitor opinion: Genasense Datamonitor opinion: Orathecin APPENDIX Glossary of terms Websites Cancer information Drug information Pharmaceutical companies Biotechnology companies References Master table of pipeline compounds Ordering: Order Online - visit http://www.researchandmarkets.com/reports/973 Order by Fax - using the order form below Order By Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Printed 30/08/2008 14:06:19 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com Order information Please verify that the product information is correct and select the format you require. Product Name: Drugs of Tomorrow: Cancer Overview Web Address: http://www.researchandmarkets.com/reports/973 Office Code: OCHGMLIKTTT Report formats Please enter the quantity of the report format you require. Format Quantity Price Hard Copy €6,591.00 + EUR€ 50.00 Shipping/Handling * Electronic €6,527.00 Electronic - Site License €6,527.00 * Shipping/Handling is only charged once per order. Contact information Please enter all the information below in BLOCK CAPITALS. First Name:   Last Name:   Email Address: Job Title: Organisation: Address: City: Postal/Zip Code: Country: Phone Number: Fax Number: Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World Page 2 of 2 Printed 30/08/2008 14:06:19 Payment information Please indicate the payment method you would like to use by selecting the appropriate box.  Pay by Credit Card: American Express Diners Club Master Card Visa Cardholder Name: Expiry Date: / Card Number: CVV Security Code: Issue Date: /   (Diners Club only)  Pay by Check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.  Pay by Wire Transfer: Please transfer funds to: Account number: 83313083 Sort code: 98-53-30 Swift code: ULSBIE2D IBAN number: IE78ULSB98533083313083 Bank Address: Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World